Literature DB >> 23600561

Relative contributions of insulin resistance and β-cell dysfunction to the development of Type 2 diabetes in Koreans.

C-H Kim1, H-K Kim, E H Kim, S J Bae, J-Y Park.   

Abstract

AIMS: Controversies still exist regarding the relative contributions of insulin resistance and β-cell dysfunction to the pathogenesis of Type 2 diabetes in different populations. We examined the associations of baseline insulin resistance and β-cell function indices with the development of Type 2 diabetes in Koreans.
METHODS: We analysed the clinical and laboratory data of 17 878 Korean adults (age 20-79 years) who underwent routine medical examinations with a median interval of 3.5 years (range 2.5-4.7 years). Using the homeostasis model assessment, insulin resistance (HOMA-IR) and β-cell function (HOMA-%B) indices at baseline were assessed.
RESULTS: Those who developed diabetes (n = 732, 4.1%) had significantly higher fasting serum insulin level (53.4 ± 31.2 vs. 41.4 ± 23.4 pmol/l) and HOMA-IR (2.38 ± 1.45 vs. 1.65 ± 1.02) and lower HOMA-%B (74 ± 47 vs. 85 ± 48) at baseline (P < 0.001 for all). Both high HOMA-IR and low HOMA-%B were independently associated with an increased odds ratio of incident Type 2 diabetes. Among the participants who developed diabetes, 29% demonstrated predominant β-cell dysfunction (HOMA-%B < 25th percentile) and 51% had predominant insulin resistance (HOMA-IR > 75th percentile). When we divided the participants according to the median BMI of the whole population (23.7 kg/m²), 49% of participants in the low BMI group demonstrated predominant β-cell dysfunction and 26% had predominant insulin resistance, whilst 21% in the high BMI group demonstrated mainly β-cell dysfunction and 60% had mainly insulin resistance.
CONCLUSIONS: In individuals with low BMI, β-cell dysfunction is the predominant defect, whereas insulin resistance is the predominant pathogenetic factor in individuals with high BMI in the development of Type 2 diabetes in Koreans.
© 2013 The Authors. Diabetic Medicine © 2013 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23600561     DOI: 10.1111/dme.12201

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  10 in total

1.  Early-stage chronic kidney disease, insulin resistance, and osteoporosis as risk factors of sarcopenia in aged population: the fourth Korea National Health and Nutrition Examination Survey (KNHANES IV), 2008-2009.

Authors:  J E Kim; Y-H Lee; J H Huh; D R Kang; Y Rhee; S-K Lim
Journal:  Osteoporos Int       Date:  2014-05-21       Impact factor: 4.507

2.  The Effect of Bariatric Surgery on Asian Patients with Type 2 Diabetes Mellitus and Body Mass Index < 30 kg/m2: a Systematic Review and Meta-analysis.

Authors:  Guangnian Ji; Pengzhou Li; Weizheng Li; Xulong Sun; Zhaomei Yu; Rao Li; Liyong Zhu; Shaihong Zhu
Journal:  Obes Surg       Date:  2019-08       Impact factor: 4.129

Review 3.  HOMA-IR as a predictor of Health Outcomes in Patients with Metabolic Risk Factors: A Systematic Review and Meta-analysis.

Authors:  José G González-González; Jorge R Violante-Cumpa; Miguel Zambrano-Lucio; Erick Burciaga-Jimenez; Patricia L Castillo-Morales; Mariano Garcia-Campa; Ricardo César Solis; Alejandro D González-Colmenero; René Rodríguez-Gutiérrez
Journal:  High Blood Press Cardiovasc Prev       Date:  2022-10-01

4.  Helminth infections and type 2 diabetes: a cluster-randomized placebo controlled SUGARSPIN trial in Nangapanda, Flores, Indonesia.

Authors:  Dicky L Tahapary; Karin de Ruiter; Ivonne Martin; Lisette van Lieshout; Bruno Guigas; Pradana Soewondo; Yenny Djuardi; Aprilianto E Wiria; Oleg A Mayboroda; Jeanine J Houwing-Duistermaat; Hengki Tasman; Erliyani Sartono; Maria Yazdanbakhsh; Johannes W A Smit; Taniawati Supali
Journal:  BMC Infect Dis       Date:  2015-03-18       Impact factor: 3.090

5.  A Pilot Study Evaluating Steroid-Induced Diabetes after Antiemetic Dexamethasone Therapy in Chemotherapy-Treated Cancer Patients.

Authors:  Yusook Jeong; Hye Sook Han; Hyo Duk Lee; Jiyoul Yang; Jiwon Jeong; Moon Ki Choi; Jihyun Kwon; Hyun-Jung Jeon; Tae-Keun Oh; Ki Hyeong Lee; Seung Taik Kim
Journal:  Cancer Res Treat       Date:  2016-02-29       Impact factor: 4.679

6.  Predictive Value of Glucose Parameters Obtained From Oral Glucose Tolerance Tests in Identifying Individuals at High Risk for the Development of Diabetes in Korean Population.

Authors:  Hae Kyung Yang; Hee-Sung Ha; Marie Rhee; Jin-Hee Lee; Yong-Moon Park; Hyuk-Sang Kwon; Hyeon-Woo Yim; Moo-Il Kang; Won-Chul Lee; Ho-Young Son; Seung-Hwan Lee; Kun-Ho Yoon
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

7.  Clinical Characteristics of People with Newly Diagnosed Type 2 Diabetes between 2015 and 2016: Difference by Age and Body Mass Index.

Authors:  Kyoung Hwa Ha; Cheol Young Park; In Kyung Jeong; Hyun Jin Kim; Sang Yong Kim; Won Jun Kim; Ji Sung Yoon; In Joo Kim; Dae Jung Kim; Sungrae Kim
Journal:  Diabetes Metab J       Date:  2018-04       Impact factor: 5.376

8.  Influence of Diabetic Retinopathy on the Relationship Between Body Mass Index and Mortality in Patients with Poorly Controlled Type 2 Diabetes.

Authors:  Yu-Hsuan Li; Wayne Huey-Herng Sheu; I-Te Lee
Journal:  Diabetes Metab Syndr Obes       Date:  2020-03-24       Impact factor: 3.168

9.  Association Between Aspartate Aminotransferase to Alanine Aminotransferase Ratio and Incidence of Type 2 Diabetes Mellitus in the Japanese Population: A Secondary Analysis of a Retrospective Cohort Study.

Authors:  Lidan Chen; Kebao Zhang; Xue Li; Yang Wu; Qingwen Liu; Liting Xu; Liuyan Li; Haofei Hu
Journal:  Diabetes Metab Syndr Obes       Date:  2021-11-09       Impact factor: 3.168

10.  A 70% Ethanol Extract of Mistletoe Rich in Betulin, Betulinic Acid, and Oleanolic Acid Potentiated β-Cell Function and Mass and Enhanced Hepatic Insulin Sensitivity.

Authors:  Byoung-Seob Ko; Suna Kang; Bo Reum Moon; Jin Ah Ryuk; Sunmin Park
Journal:  Evid Based Complement Alternat Med       Date:  2016-01-14       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.